Health News for Senior Citizens
Health News for Seniors
One Brave Idea will try to eliminate top killer of senior citizens - cardiovascular disease
Seeking leader, team to use $75 million in bold new approach
Jan. 14, 2016—The American Heart Association (AHA) and Verily, (formerly Google Life Sciences) announced today that AstraZeneca (AZ) has joined them in a bold new approach to find a cure for coronary heart disease and improve cardiovascular health.
With a commitment of $75 million dollars over at least a five-year period, three organizations have initiated the single largest research project funding one leader and team in the fight to cure coronary heart disease. American Heart Association (AHA) and Verily, (formerly Google Life Sciences) announced today that AstraZeneca (AZ) has joined them in a bold new approach to be known as One Brave Idea.
The application period for this new research enterprise officially opens today at 5:00 PM ET at: www.onebraveidea.com.
One of every three deaths in the U.S. in 2013 were from heart disease, stroke and other cardiovascular diseases, while heart disease and stroke were the No. 1 and No. 2 killers worldwide, according to American Heart Association’s report released in December - 2016 Heart Disease and Stroke Statistics Update.
An estimated 83.6 million American adults had CVD, according to Older Americans & Cardiovascular Diseases, published by the American Heart Association in 2013. More than half of these patients - 42.2 million - were estimated to be age 60 or older. This report also found:
· About 80% of people who die of Coronary Heart Disease (CHD) are age 65 or older.
· For the 60–79-year-old age group, the following have CHD: 21.1% of men; 10.6% of women.
· For the 80+year-old age group, the following have CHD: 34.6% of men; 18.6% of women.
· Average age of first heart attack is 64.7 years for men and 72.2 years for women.
· In part because women have heart attacks at older ages than men do, they’re more likely to die from them within a few weeks.
The three organizations have joined forces to find one brave idea from a visionary leader. This person and their team will be awarded the opportunity and challenge to make a difference for the millions of people directly affected by coronary heart disease.
Their goal: prevent or reverse coronary heart disease and its consequences, therein restoring cardiovascular health.
Launched as One Brave Idea, this research model will provide a specialized team of interdisciplinary experts with the stability and support needed for at least five years of well-funded research. This model is also designed to accelerate discovery by removing the barriers and the silos that plague the traditional research process.
“We are trying to do something disruptive here,” said Nancy Brown, Chief Executive Officer of the American Heart Association. “This is our moonshot - it’s an unprecedented opportunity for the world’s best and brightest to address a leading health threat. It all starts with the search for a leader and a vision to end coronary heart disease.”
Cardiovascular diseases are the No. 1 cause of death globally, accounting annually for approximately 17 million deaths, or about one of every three deaths. Coronary heart disease itself is responsible for more than 7 million deaths annually.
“We want to create a model for experts from different disciplines to come together and focus on a problem,” said Andrew Conrad, Chief Executive Officer of Verily. “Our aim is to provide the resources and support necessary to study coronary heart disease over a number of years with the most advanced tools available. We’re looking for a team that can gain new understanding, prove new treatments, and - ultimately - prevent or reverse this challenging disease.”
The selected leader and their team will have resources beyond the financial investment of the organizations by combining the AHA's medical and scientific expertise, Verily's technical prowess, and scientific insights and mentoring from AstraZeneca. A Joint Leadership Group comprised of 2-3 leaders from each funding organization will guide, advise and resource the selected leader and the new research enterprise.
“AstraZeneca is continually looking for new ways to enable cross sector collaboration amongst individuals, organizations and communities who share our passion for patients,” said Gregory Keenan, MD, Vice President and Head of US Medical Affairs, AstraZeneca.
“This research allows us to combine resources to improve cardiovascular health – and take a truly innovative approach to solving issues of cardiovascular disease in a multidisciplinary way.”
Submissions are accepted only at onebraveidea.com and are due by 11:59 pm CT on February 14, 2016.
Members of the One Brave Idea Joint Leadership Group:
Nancy Brown, CEO, American Heart Association; Robert Harrington, MD, Stanford University and AHA Board member; Joseph Loscalzo, MD PhD, Brigham and Women’s Hospital/Harvard Medical School and Chairman of the AHA’s Institute for Precision Cardiovascular Medicine; Andrew Conrad, PhD, Chief Executive Officer, Verily; Jessica Mega, MD, MPH, Chief Medical Officer, Verily; Michael V. McConnell, MD, MSEE, Head, Cardiovascular Health Innovations, Verily; Gregory Keenan, MD, Vice President & Head of US Medical Affairs, AstraZeneca; Bruce Cooper, MD, Vice President & Head of Global Medical Affairs, AstraZeneca.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – America’s No. 1 and No. 5 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
Verily, formerly Google Life Sciences, is focused on helping to move healthcare from reactive to proactive. Combining expertise from the fields of biology, chemistry, physics, medicine, electrical engineering and computer science, we’re developing new technology tools for physicians that can integrate easily into daily life and help transform the detection, prevention, and management of disease.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.